Myeloid Cells in Circulation and Tumor Microenvironment of Colorectal Cancer Patients with Early and Advanced Disease Stages

• Published in: Journal of immunology research 2020-01, Vol.2020 (2020), p.1-10
• Main Authors: Abu Nada, Mohamed, Murshed, Khaled, Khalaf, Sarah, Toor, Salman M., Elkord, Eyad
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antigen-presenting cells; Blood & organ donations; Cancer; Case-Control Studies; Cloning; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - blood; Colorectal Neoplasms - pathology; Colorectal Neoplasms - therapy; Female; Flow cytometry; Humans; Immunology; Immunophenotyping; Immunotherapy; Leukocyte Count; Leukocytes (mononuclear); Male; Metastasis; Middle Aged; Monocytes; Myeloid Cells; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neutrophils; Peripheral blood mononuclear cells; Studies; Suppressor cells; Tumor Microenvironment; Tumorigenesis; Young Adult
• ISSN: 2314-8861; 2314-7156
• DOI: 10.1155/2020/9678168

Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of cells that have been implicated in the development of an immunosuppressive environment, which promotes tumorigenesis and tumor progression. Numerous studies have reported expansion of MDSCs in circulation and the tumor microenvironment (TME) of cancer patients. However, due to the heterogenic nature of MDSCs and the different approaches for their identification, their detailed characterization and impact on disease progression in cancer patients are warranted. In this study, we investigated the levels of different myeloid cell subsets and antigen-presenting cells (APCs) using flow cytometry in unfractionated whole blood (WB), peripheral blood mononuclear cells (PBMCs), tumor tissue (TT), and adjacent normal tissue (NT) of colorectal cancer (CRC) patients. We found high levels of granulocytic myeloid cells (GMCs) in whole blood, but their levels were significantly lower in PBMCs. Importantly, we found significantly higher levels of GMCs in the TME compared to NT. In addition, monocytic myeloid cells (MMCs) showed significantly higher levels in PBMCs of CRC patients, compared to healthy donors (HDs). Notably, patients with advanced disease stages showed significantly higher levels of GMCs compared to early stages in whole blood, but PBMCs and tumor-infiltrating myeloid cells did not show any significant differences. Lastly, we found that levels of GMCs decreased, while IMCs increased in the TME with tumor budding. Our results highlight the importance of investigating the levels of different myeloid cell subsets in PBMCs versus whole blood of cancer patients and improve current knowledge on the potential prognostic significance of myeloid cells in CRC patients.